Pancreatic Cancer Drug Daraxonrasib Triggers Wave of Patient Requests Across the US
A promising new pancreatic cancer drug is reshaping conversations in oncology clinics across the United States. Demand for daraxonrasib, an experimental once-daily pill developed by Revolution Medicines, has skyrocketed following striking clinical trial results. Cancer centers nationwide are now scrambling to manage an avalanche of patient inquiries while awaiting what many believe will be quick approval from the Food and Drug Administration (FDA).
A Sudden Spike in Patient Interest
On May 1, the FDA officially approved an expanded access program for daraxonrasib. The decision came just three weeks after Revolution Medicines revealed that its drug had effectively doubled survival rates in patients battling advanced pancreatic cancer.
Pancreatic cancer is widely regarded as one of the most aggressive and unforgiving forms of the disease, with one of the lowest five-year survival rates among major cancers. For patients with limited options, the prospect of a more effective treatment has triggered enormous anticipation and hope.
“The public caught wind of the FDA announcement, which has triggered a deluge of patient requests,” said Dr. Daniel King, a medical oncologist at Northwell Health’s Zuckerberg Cancer Center. He added that institutions are still figuring out how to open up the protocols and offer access without overwhelming their internal systems.
Why This Drug Matters
Daraxonrasib targets a specific genetic mutation found in roughly 90 percent of pancreatic cancers, giving it a remarkably broad reach within the patient population. The clinical trial results have stunned many in the oncology field.
Key findings include:
- Median patient survival increased to 13.2 months
- Standard chemotherapy showed a median survival of just 6.7 months
- The pill is taken just once a day, simplifying treatment routines
- It targets a mutation present in the vast majority of pancreatic cancer cases
“Doubling survival compared to best available chemotherapy is a big deal,” noted Dr. Gulam Manji, co-director of the pancreas center at Columbia/New York-Presbyterian. He emphasized that although the drug is not a cure, it represents a significant leap forward and lays the groundwork for further innovation.
Unprecedented Patient Demand
The interest from patients has been so intense that some oncologists describe it as unlike anything they have experienced. Dr. Manji recalled that in his decade-long career, he had requested compassionate use of an experimental drug only once. Yet recently, seven patients asked about daraxonrasib in just one day.
Dr. Vincent Chung, a pancreas cancer specialist at City of Hope, echoed the sentiment, noting that patients are already aware of the press releases and have begun reaching out directly. The challenge now lies in navigating an early access pathway that is significantly more complex than a typical prescription process.
How Early Access Works
Unlike FDA-approved drugs that can be prescribed routinely, daraxonrasib requires a multi-step approval process. Here is how it currently unfolds:
- Physicians submit individual patient requests to Revolution Medicines.
- If the company finds the case appropriate, the request is forwarded to the FDA.
- Hospital review boards oversee patient eligibility and monitoring.
- Doctors must report any serious side effects to regulatory authorities.
This process places significant demands on cancer centers, requiring time, staff coordination, and administrative resources that many institutions did not anticipate.
“Given the volume, I am not sure what will happen on the FDA side. I’m sure they don’t want to have 10,000 applications at once,” Dr. Chung said. He suggested that the agency may eventually develop a broader enrollment system to handle the surge efficiently.
An Expedited Path to Approval
Daraxonrasib was one of the first drugs accepted into the FDA’s newly established expedited review process. Under this pathway, the agency could potentially approve the drug within one to two months of receiving a complete submission, dramatically shortening the typical timeline.
Mark Goldsmith, CEO of Revolution Medicines, recently confirmed during a conference call that the company is fully committed to advancing the drug. However, he declined to share specific patient numbers or a timeline for the next stage of FDA submission, emphasizing only that the team is moving at full speed.
The Redwood City, California-based company has not provided additional public statements on early access inquiries at this time.
A High-Profile Patient Story
Public attention around daraxonrasib intensified after former Nebraska U.S. Senator Ben Sasse disclosed on “60 Minutes” that he has been diagnosed with Stage 4 pancreatic cancer and is currently taking the Revolution Medicines drug. His openness about the treatment has resonated with patients and families nationwide, further fueling demand and curiosity about the therapy.
A Glimpse into the Bigger Picture
The momentum surrounding daraxonrasib reflects a larger shift in cancer treatment toward precision medicine, where therapies are designed to target specific genetic features of tumors rather than relying on traditional broad-spectrum treatments.
Dr. Marty Makary, the former FDA Commissioner who recently stepped down following disagreements with administration officials, had previously praised the agency’s expedited voucher program as a major step in accelerating access to life-saving drugs. Daraxonrasib’s progress is now considered one of its most notable success stories.
What’s Next for Patients and Physicians
For patients facing one of the most difficult cancer diagnoses, daraxonrasib offers a rare glimmer of hope. While early access programs come with logistical challenges and uncertainty, the drug’s potential to extend life and pave the way for future breakthroughs has injected renewed optimism into the oncology community.
As approval moves closer and the FDA fine-tunes its processes, families, doctors, and researchers will be watching closely to see whether daraxonrasib becomes a defining milestone in the fight against pancreatic cancer.
Author
